PIPELINE

Obesity & liver diseases

Product Name

Preclinical

Phase 1

Phase 2

Phase 3

Status¹

Preclinical

Phase 1

Phase 2

Phase 3

Pemvidutide
(ALT-801)

Obesity

55%

Status²

MOMENTUM Obesity trial top line 48-wk results in Q4 2023

Pemvidutide
(ALT-801)

NASH

55%

Status²

IMPACT Phase 2b NASH trial top line data in Q1 2025

Preclinical

Phase 1

Phase 2

Phase 3

HepTcell^™

Chronic HBV

55%

Status²

Top line data in Q1 2024

¹ Expected Dates